Cogent Biosciences (COGT) Leerink Global Healthcare Conference 2026 summary

Company overview and leadership

• Focused on developing and commercializing small molecule therapies for rare, mutation-driven diseases, with bezuclastinib as the lead asset in three indications: two forms of systemic mastocytosis and gastrointestinal stromal tumors (GIST).

• Pivotal studies for all three indications read out positively in the second half of 2025, with commercial launches expected between late 2026 and early 2027.

• Leadership team has deep experience in oncology and rare diseases, with roots in successful drug development at Array BioPharma and other major pharma companies.

Market opportunity and competitive landscape

• Non-advanced systemic mastocytosis (ISM) represents a $3.5–$4 billion global market, with 6,000–8,000 treatable patients in the U.S. and a similar number in Europe.

• Bezuclastinib targets a broader patient population than its main competitor, avapritinib, and demonstrates superior efficacy and safety in clinical trials.

• Physicians are increasingly considering bezuclastinib as a first-line therapy due to its efficacy and safety profile, with discussions emerging about the potential for functional cures.

Product differentiation and clinical data

• Bezuclastinib is highly selective for KIT and non-CNS penetrant, reducing off-target side effects seen with avapritinib.

• Demonstrates nearly double the symptomatic improvement compared to avapritinib and a higher rate of biomarker response.

• Expanded access programs are in place for both GIST and mastocytosis, reflecting strong demand from physicians and patients.